Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -3.03% 96.00 95.20 95.40 102.00 95.20 102.00 1,348,628 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -29.4 -36.8 - 126

4d Pharma Share Discussion Threads

Showing 12226 to 12248 of 12250 messages
Chat Pages: 490  489  488  487  486  485  484  483  482  481  480  479  Older
DateSubjectAuthorDiscuss
20/10/2020
23:34
Not all placings are bad, I believe sooner or later 4d will need more funds to progress and not just to keep the lights on. I do feel looking at the price action from the IBS trial RNS that a placing is indeed doing the rounds and those involved forward sold on the news. the price has stabalised at around 95-100p which tells me if there is a placing it will be between 80-90p. Remember any placing here is to progress the company.
katsy
20/10/2020
23:06
Just noticed this story Prothena getting $60m as a milestone payment for progression of a clinical trial with Roche in Parkinsons Disease Look forward to news on our CNS programmes htTps://investegate.co.uk/prothena-corporation-plc/gnw/roche-and-prothena-will-advance-prasinezumab-into-late-stage-clinical-development-study-in-parkinson--8217-s-disease/20201020210510H9980/ Part of an earlier $600m headline agreement Roche And Prothena Enter Into Worldwide Collaboration To Co-Develop And Co-Promote Antibodies For Treatment Of Parkinson's Disease "Prothena to receive up to $600 million, inclusive of upfront payment and near-term clinical milestone totaling $45 million, as well as 30 percent of U.S. profits, and up to double-digit royalties on ex-U.S. net sales"
the stigologist
20/10/2020
22:46
Stig, it's a bb, you must realise people appreciate the superb scientific and technical info provided here by many, yourself included, there is absolutely no point in engaging with those that are paid in lollipops....Any investor with an ounce of intelligence will see things for what they are....
daveweld2
20/10/2020
22:12
A few little trumps,but the potential here,the backing from the directors and major investors makes it a lot more chilled
hillfoot7
20/10/2020
22:05
Doom mongers etc, are you panicking, it seems so to me.
royalalbert
20/10/2020
21:54
Just could do with a Ronnie Corbett in goal at the moment
hillfoot7
20/10/2020
21:26
Yur beginning to sound v.desperate.
stigofthedump
20/10/2020
19:58
1. They have raised at big discounts TWICE already this year 2. If the stock is cheap why not buy as much as possible in a mates rates 'Friends and Family' round prior to a NASDAQ listing ? 3. Why do any genuine longs with brain cells care if there is more dilution at these levels given the huge potential ? Do you not want them to progress their various pipelines ? 4. The scum who try to talk stocks down on '[scary]Placing[/scary]" rumours can only do so based on Investors being cucks who get scared by such b.s.
the stigologist
20/10/2020
19:47
What makes you say that Welsh boy. I certainly don't see any need for a fundraiser, might be wrong but the management chose not to raise more earlier in the year. They know why and I expect they know that money is coming their way, probably from merck.
devonlad
20/10/2020
19:29
Have you been tipped off about a placing?
hodr
20/10/2020
18:40
Looks all set for fund raise at circa 85p by the end of the week Pob Lwc to you all........................
welshboy
20/10/2020
18:37
Shorter gays here again
gooner1886
20/10/2020
18:22
8 thumbs up tells you what people are expecting imo
ronwilkes123
20/10/2020
17:20
No cash here boys - big discounted fund raise coming up.
yellowdog
20/10/2020
17:02
I thought they said the IBS result was like winning a gold medal but not a world record....! Maybe IBS is like winning a gold at tidly winks in comparison to MRx0518 which is the 100m
1airbag
20/10/2020
17:01
Drewster, your article highlights exactly why DDDD is so good at what they are doing, its because they are studying in great detail everything about the single strains of gut bacteria they are using. It is also one of the reasons they are using single strains, unlike some of the competition.
swallowsflysouth
20/10/2020
16:59
well if they get to PH3 in a year with Mrx0518 in combo with Keytruda, forget poxy £100m valuations.
1airbag
20/10/2020
16:52
some more background about the microbiome: hTTps://medicalxpress.com/news/2020-10-gut-bacteria-multiple-sclerosis-probiotic.amp
the drewster
20/10/2020
15:35
4D actually told us the opposite and IBS is likely to go to P3 but need partner first.
blueblood
20/10/2020
15:17
If you read DP's interview transcript he is saying regulators didn't know anything about how to tackle LBT in the early days. 4D's own CMO was involved in defining some regulations for LBT. Safety is of primary importance followed closely by efficacy so yes I do agree despite FDA's stringent procedures/processes they could favour a 'fast path' approach to getting LBT 'drugs' to the market quicker than normal. Fingers crossed, all looking rosy. P.S. Folks who are saying there is still life left in Blutix & IBS have a perfectly valid claim as phase 3 cannot be ruled out at this stage. At least not until 4D say so.
frrinvest
20/10/2020
15:01
Thank you Ozzywalker and Bms1a3c !
thresholdbypass
20/10/2020
14:55
Re fast track....I seem to remember this was covered in one of the longer interviews over the summer (during analyst questions)The comment I remember was FDA had been engaged and they wanted to see data from about 100 patients first
bms1a3c
20/10/2020
14:43
https://www.fiercepharma.com/pharma/merck-s-keytruda-scores-solo-lymphoma-nod-but-analysts-are-fixed-seagen-s-combo-potentialThis article has some interesting points about fast tracking drugs to market.
ozzywalker
Chat Pages: 490  489  488  487  486  485  484  483  482  481  480  479  Older
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201021 02:21:09